Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Legiec, A." wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    What is the Real Issue with Floating Storage and Regasification Units? Regulations Related to the FSRU Implementation Process in the Baltic Sea
    Autorzy:
    Koska-Legieć, A.
    Powiązania:
    https://bibliotekanauki.pl/articles/116861.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Morski w Gdyni. Wydział Nawigacyjny
    Tematy:
    Baltic Sea
    Floating Storage and Regasification Unit (FSRU)
    Floating Storage Unit (FSU)
    Liquefied Natural Gas (LNG)
    maritime law
    LNG transportation
    law implementation
    national legal system
    Opis:
    The aim of this article is to dispel any nomenclatural confusion related to the notion of FSRU. Sometimes FSRUs are classified as ships or vessels; sometimes as stationary units. The article will attempt to explain in which case FSRUs may be classified as ships. This article describes one of the most persistent legal problems in Polish maritime law, which is the FSRU implementation in the Baltic Sea. The application of FSRU solutions was analysed in relation to LNG maritime transport. This analysis is concerned only with a fragment of wider theoretical considerations about the placement of the definition of the ship in different national legal systems as well as the importance of translation and correct understanding of the words denoting the ship or the vessel.
    Źródło:
    TransNav : International Journal on Marine Navigation and Safety of Sea Transportation; 2018, 12, 3; 499-503
    2083-6473
    2083-6481
    Pojawia się w:
    TransNav : International Journal on Marine Navigation and Safety of Sea Transportation
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma
    Autorzy:
    Szudy-Szczyrek, A.
    Legiec, W.
    Mańko, J.
    Gmyz, K.
    Szczyrek, M.
    Hus, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/2052439.pdf
    Data publikacji:
    2015
    Wydawca:
    Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
    Tematy:
    multiple myeloma
    immunomodulatory drugs
    maintenance therapy
    lenalidomide
    Opis:
    Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.
    Źródło:
    Health Problems of Civilization; 2015, 09, 2; 50-54
    2353-6942
    2354-0265
    Pojawia się w:
    Health Problems of Civilization
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies